Global respiratory trainer market, by Product Type (Resistance Training Devices and Endurance Training Devices), by Technique (Inspiratory Muscle Training, Expiratory Muscle Training, and Combination of Both), by Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease, and Others), by End User (Children and Adults), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) is estimated to be valued at US$ 481.83 Million in 2022 and projected to exhibit a CAGR of 7.3% during the forecast period (2022-2030).
Key players are involved in initiating new respiratory muscle strength training (RMST) programs for patients. This is expected to drive market growth over the forecast period. For instance, as per the website of Aspire Respiratory Products, a manufacturer of respiratory trainer device, it initiated respiratory muscle strength training (RMST) for patients, which provides training to patients for impairments in speech, voice, cough, and/or swallowing. The primary goal of the training is to increase the capacity of inspiratory and expiratory muscles.
Global Respiratory Trainer Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic has affected various industries globally. Key players operating in the global respiratory trainer market are facing major challenges on various fronts due to the COVID-19 pandemic. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported globally, as of May 27, 2022, are approximately 525,467,084 confirmed cases with 6,285,171 deaths.
Key players in market are focusing on developing new respiratory trainers to combat Covid-19 symptoms by planning and conducting clinical trials.
For instance, on October 13, 2021, PN Medical, a developer of cardiopulmonary devices, entered into a collaboration with Mayo Clinic, in order to conduct a clinical trial, which helped to identify new approaches that would treat the symptoms of the post-acute COVID Syndrome. The clinical trial, in this case, was a completely virtual study. During the clinical trial, the participants received PN Medical's respiratory muscle training device (BREATHER FIT) and followed a training plan on the BREATHER COACH connected app that required using the device up to two times a day on a specific number of days per week to test its effectiveness in reducing long term COVID symptoms.